A phase II study of neoadjuvant biochemotherapy for stage III melanoma

Cancer

Volumn 94, Issue 2, 2002, Pages 470-476

  Gibbs, Peter ^a   Anderson, Clay ^b   Pearlman, Nathan ^c   LaClaire, Stacy ^d   Becker, Maude ^c   Gatlin, Kristi ^c   O'Driscoll, Martin ^e   Stephens, Janet ^c   Gonzalez, Rene ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO HOSPITAL   (United States)

^e ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biochemotherapy; Lymph nodes; Melanoma; Stage III; Therapy

Indexed keywords

CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PILOT PROJECTS; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0037080109     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10186     Document Type: Article

References (8)

1. Therapeutic node dissections in malignant melanoma
2. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
3. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease
4. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma
5. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
6. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases
7. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, inteferon alfa, and interleukin-2 for patients with metastatic melanoma
8. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interluekin 2, and interferon alpha-2B in patients with metastatic melanoma